Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077363 · ClinicalTrials.gov registry record · Phase 2
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00077363: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00077363 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077363, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving capecitabine together with tipifarnib works in treating women with taxane-resistant metastatic breast cancer. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving capecitabine together with tipifarnib may kill more tumor cells
Interventions
- DRUG capecitabine
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077363
The ClinicalTrials.gov registry entry for NCT00077363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which capecitabine is the first listed.
NCT00077363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077363 about?
NCT00077363 is a clinical study titled "Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer". This phase II trial is studying how well giving capecitabine together with tipifarnib works in treating women with taxane-resistant metastatic breast cancer. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Tipifa...
What is the current status of trial NCT00077363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00077363?
The interventions under investigation include: capecitabine (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00077363?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.